Call Us

ARTICLES

Arthrosamid®’s story started two decades ago. The brainchild of the team at Contura, the product had been in human use for various indications since 2000, and a favourable safety profile had already been established.

PATIENTS GAIN ACCESS TO INNOVATIVE NEW PROCEDURE FOR TREATING KNEE OSTEOARTHRITIS AS HCA UK PARTNERS WITH CONTURA ORTHOPAEDICS

London, September 2022; Contura Orthopaedics Ltd is pleased to announce that a major hospital group has signed up to Arthrosamid, allowing clinicians to offer this novel procedure to its patients in London and across the UK.

musculoskeletal disorders in addition to sporting injuries and complaints at its state-of-the-art facility located on Tottenham Court Road in Central London. The treatment will be rolled out across other facilities across the HCA Healthcare UK group in the coming months.

Arthrosamid is a polyacrylamide hydrogel first developed by Contura International Ltd. It is a long-lasting intra-articular injection approved in Europe for the treatment of knee OA. The treatment has the potential to change the present care pathway for managing OA, which affects approximately

Why Knee Osteoarthritis Remains Incurable Despite Therapeutic Advancements

Knee osteoarthritis, a common condition causing chronic pain and reduced mobility, remains incurable due to the unique avascular biology of knee cartilage and limited self-repair capacity. Despite advancements in stem cell and gene therapies, current treatments primarily offer symptom relief rather than full cartilage restoration. The disease’s progressive nature, complex causes, and patient variability further complicate effective treatment development. Regulatory and clinical hurdles delay the transition of promising therapies to clinical use. Ongoing research focuses on innovative, personalized approaches to stimulate cartilage repair and overcome these challenges, offering hope for future breakthroughs that could transform management and quality of life for millions affected worldwide.

Read More »

Assessing the Clinical Impact of Arthrosamid on Medial-Compartment Knee Osteoarthritis: Mechanisms, Efficacy, Safety and Future Directions

Arthrosamid® is a novel polyacrylamide hydrogel injection offering targeted, long-lasting relief for medial-compartment knee osteoarthritis, affecting millions worldwide. Unlike traditional treatments, Arthrosamid® delivers mechanical cushioning and improved joint lubrication through a single outpatient procedure, reducing pain and enhancing mobility. Clinical studies report significant symptom improvement lasting up to two years with minimal side effects, bridging the gap between medication and surgery. Ideal for patients unresponsive to conservative therapies, Arthrosamid® supports knee stability and quality of life. Ongoing research aims to validate long-term benefits and explore synergy with regenerative treatments, making Arthrosamid® a promising advancement in osteoarthritis care.

Read More »